Literature DB >> 32152624

Cumulative Histologic Inflammation Predicts Colorectal Neoplasia in Ulcerative Colitis: A Validation Study.

Olivia V Yvellez1, Victoria Rai1, Philip H Sossenheimer1, John Hart1, Jerrold R Turner2, Christopher Weber1, Katia El Jurdi1, David T Rubin1.   

Abstract

BACKGROUND: Chronic inflammation in ulcerative colitis (UC) is associated with the development of colorectal neoplasia (CRN). A group at St. Mark's Hospital reported a novel cumulative inflammatory index that predicted the development of CRN in UC patients that we validated with an independent, well-described, matched, case-controlled cohort from the University of Chicago.
METHODS: Cumulative inflammatory burden (CIB) was calculated by summing each histological inflammatory activity (HIA) score and multiplying it by the length of the surveillance interval. Persistency was defined by the number of surveillance episodes (with a severity score >2) divided by the total number of surveillance procedures. T tests compared the mean and maximum HIA scores, assessing mean and maximum severity, CIB, and persistency.
RESULTS: Sixty-two UC patients (26 patients with CRN, 36 control patients without CRN) were analyzed. Fifty-five percent were men, mean disease duration was 20.6 years, and mean age at CRN diagnosis was 43.9. Of the CRN patients, 6 (23%) had colorectal cancer, 16 (62%) had low-grade dysplasia, and 4 (15%) had indefinite dysplasia. Using mean HIA scores, we found CIB to be statistically greater in CRN patients (P = 0.04). Using maximum HIA scores, we found CIB (P = 0.02), mean severity (P = 0.03), and persistency (P = 0.01) to be significantly greater in CRN patients. Maximum severity was numerically greater for mean and maximum HIA scores but did not reach significance.
CONCLUSION: Cumulative histologic inflammation is significantly associated with the development of CRN in UC patients. This suggests a management strategy of controlling inflammation to reduce the risk of CRN and may influence the selection of surveillance intervals.
© 2020 Crohn’s & Colitis Foundation. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  colorectal cancer; dysplasia; inflammation; ulcerative colitis

Mesh:

Year:  2021        PMID: 32152624      PMCID: PMC7813748          DOI: 10.1093/ibd/izaa047

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  13 in total

1.  Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies.

Authors:  Tine Jess; Christine Rungoe; Laurent Peyrin-Biroulet
Journal:  Clin Gastroenterol Hepatol       Date:  2012-01-28       Impact factor: 11.382

2.  Backwash ileitis is strongly associated with colorectal carcinoma in ulcerative colitis.

Authors:  U A Heuschen; U Hinz; E H Allemeyer; J Stern; M Lucas; F Autschbach; C Herfarth; G Heuschen
Journal:  Gastroenterology       Date:  2001-03       Impact factor: 22.682

3.  The risk of colorectal cancer in ulcerative colitis: a meta-analysis.

Authors:  J A Eaden; K R Abrams; J F Mayberry
Journal:  Gut       Date:  2001-04       Impact factor: 23.059

4.  Re: Cumulative burden of inflammation predicts colorectal neoplasia risk in ulcerative colitis: a large single-centre study.

Authors:  Yoshinaga Okugawa; Yuji Toiyama; Masato Kusunoki; Ajay Goel
Journal:  Gut       Date:  2018-03-13       Impact factor: 23.059

5.  ACG Clinical Guideline: Ulcerative Colitis in Adults.

Authors:  David T Rubin; Ashwin N Ananthakrishnan; Corey A Siegel; Bryan G Sauer; Millie D Long
Journal:  Am J Gastroenterol       Date:  2019-03       Impact factor: 10.864

6.  Ulcerative colitis-associated colorectal cancer shows a poorer survival than sporadic colorectal cancer: a nationwide Japanese study.

Authors:  Toshiaki Watanabe; Tsuyoshi Konishi; Junji Kishimoto; Kenjiro Kotake; Tetsuichiro Muto; Kenichi Sugihara
Journal:  Inflamm Bowel Dis       Date:  2011-03       Impact factor: 5.325

7.  Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: a case-control study.

Authors:  David T Rubin; Dezheng Huo; Jami A Kinnucan; Mina S Sedrak; Nicole E McCullom; Alana P Bunnag; Elin P Raun-Royer; Russell D Cohen; Stephen B Hanauer; John Hart; Jerrold R Turner
Journal:  Clin Gastroenterol Hepatol       Date:  2013-07-17       Impact factor: 11.382

8.  Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis.

Authors:  Matthew Rutter; Brian Saunders; Kay Wilkinson; Steve Rumbles; Gillian Schofield; Michael Kamm; Christopher Williams; Ashley Price; Ian Talbot; Alastair Forbes
Journal:  Gastroenterology       Date:  2004-02       Impact factor: 22.682

9.  Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study.

Authors:  Roopali Bansal Gupta; Noam Harpaz; Steven Itzkowitz; Sabera Hossain; Sierra Matula; Asher Kornbluth; Carol Bodian; Thomas Ullman
Journal:  Gastroenterology       Date:  2007-08-02       Impact factor: 22.682

10.  Developing a Standard Set of Patient-Centred Outcomes for Inflammatory Bowel Disease-an International, Cross-disciplinary Consensus.

Authors:  Andrew H Kim; Charlotte Roberts; Brian G Feagan; Rupa Banerjee; Willem Bemelman; Keith Bodger; Marc Derieppe; Axel Dignass; Richard Driscoll; Ray Fitzpatrick; Janette Gaarentstroom-Lunt; Peter D Higgins; Paulo Gustavo Kotze; Jillian Meissner; Marian O'Connor; Zhi-Hua Ran; Corey A Siegel; Helen Terry; Welmoed K van Deen; C Janneke van der Woude; Alandra Weaver; Suk-Kyun Yang; Bruce E Sands; Séverine Vermeire; Simon Pl Travis
Journal:  J Crohns Colitis       Date:  2018-03-28       Impact factor: 9.071

View more
  5 in total

1.  Appendiceal Orifice Inflammation Is Associated with Lower Rate of Complete Endoscopic Remission in Patients with Ulcerative Colitis.

Authors:  Chang Kyo Oh; Han Hee Lee; Jin Su Kim; Bo-In Lee; Young-Seok Cho
Journal:  J Pers Med       Date:  2022-05-05

2.  The outcome of patients with inflammatory bowel disease-associated colorectal cancer is not worse than that of patients with sporadic colorectal cancer-a matched-pair analysis of survival.

Authors:  Francesco Vitali; Axel Wein; Timo Rath; Markus Eckstein; Clemens Neufert; Jürgen Siebler; Raja Atreya; Arndt Hartmann; Werner Hohenberger; Klaus Weber; Markus Friedrich Neurath; Robert Grützmann; Susanne Merkel
Journal:  Int J Colorectal Dis       Date:  2021-12-04       Impact factor: 2.571

Review 3.  The Role of the Immune System in IBD-Associated Colorectal Cancer: From Pro to Anti-Tumorigenic Mechanisms.

Authors:  Sofía Frigerio; Dalia A Lartey; Geert R D'Haens; Joep Grootjans
Journal:  Int J Mol Sci       Date:  2021-11-25       Impact factor: 5.923

Review 4.  Autophagy in gastrointestinal cancers.

Authors:  Bo-Zong Shao; Ning-Li Chai; Yi Yao; Jin-Ping Li; Helen Ka Wai Law; En-Qiang Linghu
Journal:  Front Oncol       Date:  2022-08-26       Impact factor: 5.738

Review 5.  Colorectal Cancer in Ulcerative Colitis: Mechanisms, Surveillance and Chemoprevention.

Authors:  Wenqian Li; Tiantian Zhao; Dacheng Wu; Jiajia Li; Mei Wang; Yunyun Sun; Sicong Hou
Journal:  Curr Oncol       Date:  2022-08-25       Impact factor: 3.109

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.